TW201410246A - Ａｍｇ ９００治療癌症之用途 - Google Patents

Ａｍｇ ９００治療癌症之用途 Download PDF

Info

Publication number
TW201410246A
TW201410246A TW102119482A TW102119482A TW201410246A TW 201410246 A TW201410246 A TW 201410246A TW 102119482 A TW102119482 A TW 102119482A TW 102119482 A TW102119482 A TW 102119482A TW 201410246 A TW201410246 A TW 201410246A
Authority
TW
Taiwan
Prior art keywords
cancer
amg
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Application number
TW102119482A
Other languages
English (en)
Chinese (zh)
Inventor
Gregory Friberg
Marc Payton
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of TW201410246A publication Critical patent/TW201410246A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW102119482A 2012-05-31 2013-05-31 Ａｍｇ ９００治療癌症之用途 TW201410246A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261654021P 2012-05-31 2012-05-31

Publications (1)

Publication Number Publication Date
TW201410246A true TW201410246A (zh) 2014-03-16

Family

ID=48614183

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102119482A TW201410246A (zh) 2012-05-31 2013-05-31 Ａｍｇ ９００治療癌症之用途

Country Status (5)

Country Link
US (2) US8921367B2 (enExample)
EP (1) EP2854811A1 (enExample)
JP (2) JP2015518053A (enExample)
TW (1) TW201410246A (enExample)
WO (1) WO2013181462A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
JP6634016B2 (ja) 2013-12-03 2020-01-22 アムジエン・インコーポレーテツド Ｎ−（４−（（３−（２−アミノ−４−ピリミジニル）−２−ピリジニル）オキシ）フェニル）−４−（４−メチル−２−チエニル）−１−フタラジンアミンの薬学的に許容される塩の結晶形態及びその使用
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US10639349B2 (en) 2015-04-06 2020-05-05 The Johns Hopkins University H3T3A mutant protein efficiently reduces H3T3P and causes increased cell death of rapidly dividing cells
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
CN112898292A (zh) 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
US20220323446A1 (en) * 2021-03-17 2022-10-13 Amgen Inc. Sotorasib dosing regimen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
PL2475368T3 (pl) * 2009-09-11 2015-05-29 Amgen Inc N-(4-((3-(2-amino-4-pirymidynylo)-2-pirydynylo)oksy)fenylo)-4-(4-metylo-2-tienylo)-1-ftalazynoamina do stosowania w leczeniu raka opornego na czynniki antymitotyczne

Also Published As

Publication number Publication date
JP2015518053A (ja) 2015-06-25
US20150079022A1 (en) 2015-03-19
US8921367B2 (en) 2014-12-30
US20130323198A1 (en) 2013-12-05
JP2018138570A (ja) 2018-09-06
EP2854811A1 (en) 2015-04-08
WO2013181462A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
KR102736865B1 (ko) 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
JP7014731B2 (ja) 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法
JP6595024B2 (ja) Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
US8921367B2 (en) Use of AMG 900 for the treatment of cancer
RU2492864C2 (ru) Способ лечения рака, несущего мутации egfr
TWI535719B (zh) 咪唑并嗒
RU2695228C2 (ru) Прерывистое введение ингибитора mdm2
US20150038518A1 (en) Methods for the treatment of solid tumors
US20230321042A1 (en) Combination therapy
US11260057B2 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
CN109819649B (zh) 氨基嘌呤化合物的固体形式及其使用方法
JP2015536986A (ja) 併用療法
US9682082B2 (en) Combinations of AKT and MEK inhibitor compounds, and methods of use
JP2020143099A (ja) ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法
KR20200131251A (ko) 퀴놀론 유사체 및 이의 염, 조성물, 및 이들의 사용 방법
JP2015517523A (ja) Ｐｉ−３キナーゼ阻害剤の投与レジメン
CN118647379A (zh) 用于治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案
JP2021534115A (ja) Ｂ細胞悪性腫瘍の処置
US20230404971A1 (en) Combination Comprising Abemaciclib and 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid
TW202304424A (zh) 包含依維莫司和安森司群的組合
CN114728003A (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
US20230089371A1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN101528235A (zh) 作为vegfr3抑制剂的大环喹唑啉衍生物
HK40069821A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
HK40016954A (en) Combinations of akt and mek inhibitor compounds, and methods of use